Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Vaccine responses are decreased in solid organ transplant (SOT) recipients, and given the complexity of implementation, vaccination programs may be suboptimal. The actual burden of vaccine-preventable infections (VPIs) among SOT recipients remains unclear. To assess the incidence rate of VPIs among SOT recipients and to evaluate whether SOT recipients are at increased risk for specific VPIs compared with the general population. This nationwide cohort study used data from the Swiss Transplant Cohort Study on VPIs in individuals who underwent SOT from May 2008 to June 2019 (follow-up until December 2019) and data from the Swiss Federal Office of Public Health on notifiable VPIs in the general population in the same period. Data were analyzed from January 2021 to June 2022. Solid organ transplant. The main outcomes were the incidence rate of the following VPIs in SOT recipients: hepatitis A and B, diphtheria, Haemophilus influenzae infection, influenza, measles, mumps, pertussis, pneumococcal disease, poliomyelitis, meningococcal disease, rubella, tetanus, tick-borne encephalitis, and varicella zoster virus infection. Age-adjusted standardized incidence ratios were used to assess whether VPIs occurred more frequently in SOT recipients compared with the general population. For SOT recipients, factors associated with occurrence of VPIs were explored and the associated morbidity and mortality assessed. Of 4967 SOT recipients enrolled (median age, 54 years [IQR, 42-62 years]; 3191 [64.2%] male), 593 (11.9%) experienced at least 1 VPI. The overall VPI incidence rate was higher in the population that underwent SOT (30.57 per 1000 person-years [PY]; 95% CI, 28.24-33.10 per 1000 PY) compared with the general population (0.71 per 1000 PY). The standardized age-adjusted incidence ratio for notifiable VPIs in SOT recipients was higher compared with the general population (27.84; 95% CI, 25.00-31.00). In SOT recipients, influenza and varicella zoster virus infection accounted for most VPI episodes (16.55 per 1000 PY [95% CI, 14.85-18.46 per 1000 PY] and 12.83 per 1000 PY [95% CI, 11.40-14.44 per 1000 PY], respectively). A total of 198 of 575 VPI episodes in the population that underwent SOT (34.4%) led to hospital admission, and the occurrence of a VPI was associated with an increased risk for death and/or graft loss (hazard ratio, 2.44; 95% CI, 1.50-3.99; P = .002). In multivariable analysis, age 65 years or older at the time of transplant (incidence rate ratio [IRR], 1.29; 95% CI, 1.02-1.62) and receipt of a lung (IRR, 1.77; 95% CI, 1.38-2.26) or a heart (IRR, 1.40; 95% CI, 1.05-1.88) transplant were associated with an increased risk of VPI occurrence. In this study, 11.9% of SOT recipients experienced VPIs, and the incidence rate was higher than in the general population. There was significant morbidity and mortality associated with these infections in the population that underwent SOT, which highlights the need for optimizing immunization strategies.
Identifiants
pubmed: 37115546
pii: 2804258
doi: 10.1001/jamanetworkopen.2023.10687
pmc: PMC10148200
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2310687Investigateurs
Patrizia Amico
(P)
John-David Aubert
(JD)
Vanessa Banz
(V)
Sonja Beckmann
(S)
Guido Beldi
(G)
Christoph Berger
(C)
Ekaterine Berishvili
(E)
Annalisa Berzigotti
(A)
Isabelle Binet
(I)
Pierre-Yves Bochud
(PY)
Sandra Branca
(S)
Heiner Bucher
(H)
Emanuelle Catana
(E)
Anne Cairoli
(A)
Yves Chalandon
(Y)
Sabina De Geest
(S)
Olivier De Rougemont
(O)
Sophie De Seigneuex
(S)
Michael Dickenmann
(M)
Joëlle Lynn Dreifuss
(JL)
Michel Duchosal
(M)
Thomas Fehr
(T)
Sylvie Ferrari-Lacraz
(S)
Christian Garzoni
(C)
Déla Golshayan
(D)
Nicolas Goossens
(N)
Fadi Haidar
(F)
Jörg Halter
(J)
Dominik Heim
(D)
Christoph Hess
(C)
Sven Hillinger
(S)
Hans H Hirsch
(HH)
Patricia Hirt
(P)
Günther Hofbauer
(G)
Uyen Huynh-Do
(U)
Franz Immer
(F)
Michael Koller
(M)
Mirjam Laager
(M)
Bettina Laesser
(B)
Frédéric Lamoth
(F)
Roger Lehmann
(R)
Alexander Leichtle
(A)
Oriol Manuel
(O)
Hans-Peter Marti
(HP)
Michele Martinelli
(M)
Valérie McLin
(V)
Katell Mellac
(K)
Aurélia Mercay
(A)
Karin Mettler
(K)
Antonia Müller
(A)
Nicolas J Müller
(NJ)
Ulrike Müller-Arndt
(U)
Beat Müllhaupt
(B)
Mirjam Nägeli
(M)
Graziano Oldani
(G)
Manuel Pascual
(M)
Jakob Passweg
(J)
Rosemarie Pazeller
(R)
Klara Posfay-Barbe
(K)
Juliane Rick
(J)
Anne Rosselet
(A)
Simona Rossi
(S)
Silvia Rothlin
(S)
Frank Ruschitzka
(F)
Thomas Schachtner
(T)
Urs Schranz
(U)
Stefan Schaub
(S)
Alexandra Scherrer
(A)
Aurelia Schnyder
(A)
Macé Schuurmans
(M)
Simon Schwab
(S)
Thierry Sengstag
(T)
Federico Simonetta
(F)
Susanne Stampf
(S)
Jürg Steiger
(J)
Guido Stirnimann
(G)
Ueli Stützinger
(U)
Christian Van Delden
(C)
Jean-Pierre Venetz
(JP)
Jean Villard
(J)
Julien Vionnet
(J)
Madelaine Wick
(M)
Markus Wilhelm
(M)
Patrick Yerly
(P)
Références
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
Lancet. 2022 Aug 27;400(10353):693-706
pubmed: 36030813
Clin Ther. 2017 Aug;39(8):1581-1598
pubmed: 28751095
Clin Infect Dis. 2008 Oct 1;47(7):885-92
pubmed: 18715160
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Travel Med Infect Dis. 2018 Jul - Aug;24:89-100
pubmed: 29860151
Am J Transplant. 2020 Jan;20(1):34-39
pubmed: 31553135
Clin Infect Dis. 2020 Oct 23;71(7):e159-e169
pubmed: 31915816
World J Hepatol. 2021 Jan 27;13(1):120-131
pubmed: 33584991
Bone Marrow Transplant. 2017 Jul;52(7):1016-1021
pubmed: 28263288
Am J Transplant. 2017 Jul;17(7):1813-1822
pubmed: 28039960
Microorganisms. 2021 Jun 24;9(7):
pubmed: 34202542
Am J Transplant. 2002 Mar;2(3):287-91
pubmed: 12096793
Transplantation. 2021 Oct 1;105(10):2316-2323
pubmed: 33528118
Am J Transplant. 2021 May;21(5):1789-1800
pubmed: 33131188
Am J Cardiol. 2021 Oct 15;157:148-150
pubmed: 34373079
Am J Transplant. 2004 Jan;4(1):108-15
pubmed: 14678041
JMIR Form Res. 2022 Jan 13;6(1):e32273
pubmed: 35023840
Hum Vaccin Immunother. 2020 Nov 1;16(11):2680-2689
pubmed: 32347787
PLoS One. 2021 Apr 13;16(4):e0249785
pubmed: 33848305
Lancet Infect Dis. 2021 Jan;21(1):137-147
pubmed: 32702302
Semin Respir Crit Care Med. 2009 Apr;30(2):189-209
pubmed: 19296419
Clin Transplant. 2019 Sep;33(9):e13563
pubmed: 31002409
JAMA Pediatr. 2019 Mar 1;173(3):260-268
pubmed: 30640369
Transplantation. 2016 Mar;100(3):662-9
pubmed: 26335915
PLoS One. 2011;6(11):e27214
pubmed: 22087267
Eur J Epidemiol. 2013 Apr;28(4):347-55
pubmed: 23546766
Vaccine. 2018 Aug 16;36(34):5112-5115
pubmed: 30049629
Am J Transplant. 2007 May;7(5):1209-14
pubmed: 17286615
Transpl Infect Dis. 2020 Aug;22(4):e13343
pubmed: 32473046
JAMA Intern Med. 2022 Jun 1;182(6):585-586
pubmed: 35377405
BMJ Open. 2021 Dec 15;11(12):e051176
pubmed: 34911712
Open Forum Infect Dis. 2022 Aug 03;9(8):ofac337
pubmed: 35937651
J Pediatr. 2020 Dec;227:60-68
pubmed: 32681988
Clin Infect Dis. 2018 May 17;66(11):1698-1704
pubmed: 29253089
Front Immunol. 2021 Mar 18;12:645718
pubmed: 33815403
Am J Transplant. 2021 Jun;21(6):2246-2253
pubmed: 33565711
Clin Infect Dis. 2018 Oct 15;67(9):1322-1329
pubmed: 29635437
Hum Vaccin Immunother. 2021 Aug 3;17(8):2700-2705
pubmed: 33760692